|Bid||37.85 x 1200|
|Ask||28.50 x 1200|
|Day's Range||21.13 - 22.43|
|52 Week Range||1.75 - 26.25|
|Beta (5Y Monthly)||4.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.29|
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
Five Prime Therapeutics (FPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call